8K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): November 14,
2017
INNOVUS PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
000-52991
|
90-0814124
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File
Number)
|
(IRS
Employer Identification No.)
|
|
8845 Rehco Road,
San Diego, CA
|
|
92122
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (858) 964-5123
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR
240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR
240.13e-4(c))
In this
report, “Innovus Pharmaceuticals,” “Innovus
Pharma,” “the Company”, “we,”
“us” and “our” refer to Innovus
Pharmaceuticals, Inc., and/or one or more of our wholly-owned
subsidiaries, unless the context otherwise provides. Innovus
Pharma® is a registered service mark of Innovus
Pharmaceuticals, Inc.
Item 8.01 – Other Events
On
November 14, 2017, the Company issued a press release reporting the
launch of our FlutiCare™
OTC Nasal Spray Allergy Relief product in the U.S. FlutiCare™ was approved by the U.S. Food and
Drug Administration for OTC sale through our partner’s
approved abbreviated new drug application No. 207957. The
full text of the press release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.
Item 9.01 – Financial Statements and Exhibits
(d) Exhibits
|
Exhibit
Number
|
|
Description
|
|
|
|
Press release
issued November 14, 2017, reporting the launch of
FlutiCare™ OTC Nasal
Spray Allergy Relief in the U.S.
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this Report to be
signed on its behalf by the undersigned hereunto duly
authorized.
|
|
INNOVUS
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
Date:
November 14,
2017
|
By:
|
/S/
Bassam
Damaj
|
|
|
|
|
Bassam Damaj,
CEO
|
|
|
|
|
|
EXHIBIT
INDEX
|
Exhibit
Number
|
|
Description
|
|
|
|
Press release
issued November 14, 2017, reporting the launch of
FlutiCare™ OTC Nasal
Spray Allergy Relief in the U.S.
|